Research on the effects of our family-centered approach is an essential part of The Family Center for Bipolar Disorder's mission. Thus, during the course of treatment, we assess mood and stress, quality of life, attitude toward and knowledge of illness, and participation in and attitude toward treatment with the treating psychiatrist, in patients and caregivers. In this way, we will be able to identify aspects of patient and family adjustment that are responsive to treatment, and aspects that may be in need of enhancement. We will also be able to advance the discussion of family-centered treatment in the academic literature on Bipolar Disorder treatment -- where standards for clinical care are shaped. This work will also form the basis for the development of our ongoing research program, and our pursuit of support from private and public research funds.

An upcoming workshop at the 2007 meeting of the American Psychiatric Association will highlight The Family Center for Bipolar Disorder and its approach to treatment.

Ongoing Research Projects

• Tross S, Galynker I: Implementation and ongoing evaluation of family-oriented treatment in bipolar mood disorder.
• Galynker I, Eisneberg D: Anxiety and panic and suicidality in bipolar illness.
• DuHamel K, Tross S, Cohen L, Galynker I: Increasing Adherence in Mood Disorder Patients. Supported by NARSAD.
• Roane D, Galynker I, Brody D, Mekinulov B, Yanowitch P, Maruyama N, Kunik L, Yard S: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2000 mg/d as adjunctive therapy to an atypical antipsychotic in the treatment of manic episodes of bipolar I disorder over 6 weeks. Supported by Novartis.
• Yanowitch P, Maruyama N, Galynker I, Kunik L, Yard S: A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients With Bipolar I Depression. Supported by Pfizer.
• Galynker I, Kunik L, Maruyama N, Yanowitch P, Brody D, Grebchenko Y: A Multi-center, Double-blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR™) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period. Supported by Astra Zeneca.
• Galynker I, Yanovich , Ten A: “A randomized open label 12 month trial of Lamotrigine and Olanzapine followed by Lamotrigine monotherapy vs. standard of care Sodium Valproate for treatment of Depressed Mania. Principal Investigator.

Publications and Presentations

• Milak M, Aniskin D, Eisenberg D, Prikhojan A, Galynker I: Negative syndrome dimension in major depressive disorder, dementias, stroke, and schizophrenia. Principal component analysis of PANSS. Cognitive and Behavioral Neurology 20:113-20 (2007)
• Galynker I, Eisenberg D, Gertmenian-King E, Matochik JA, Cohen LJ, Prosser J, Kimes AS, Contoreggi C, Kurian V, Rosenthal RN, London, ED: Cerebral metabolism and mood in remitted opiate dependence. Drug Alcohol Depend. 90:166-174 (2007)
• Rosenberg Y, Mekinulov B, Cohen L, Galynker I: Restarting clozapine treatment during ablation chemotherapy and stem cell transplant for Hodgkin’s lymphoma. Am J Psychiatry 164:1438-39 (2007)
• Galynker I, Tross S, Lamphere L: Caregivers In Bipolar Families: Patients And Partners In Treatment", Study. The 160th APA Annual Meeting , San Diego, CA, May 19-24 (2007)
• Maruyama N and Atencio C: Health behaviors in bipolar patients (in press)
• Kelly Jr RE, Cohen LJ, Semple RJ, Bialer P, Lau A, Bodenheimer A, Neustadter E, Barenboim A, and Galynker II: Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Medicine: 1647-1656 (2006)
• Altman S, Cohen LJ, Ten A, Barron E, Galynker I, DuHamel KH: Predictors of relapse in bipolar disorder. Review. J Psychiatric Practice 12:269-282(2006)
• Galynker I, DuHamel K, Lamphere L, Solomainian P: What It Means To Love a Bipolar. Grand Rounds, Department of Psychiatry, Beth Israel Medical Center, March 16, 2006